Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11407747
Compositions and methods for inhibiting kinases
granted -
US 11407736
RIP1 inhibitory compounds and methods for making and using the same
granted -
US 11407820
Modulating the alternative complement pathway
granted -
US 11407800
Translatable molecules and synthesis thereof
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11407764
AhR modulators
granted -
US 11407813
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11407818
Antibodies that bind to dengue virus serotype 4 (DENV4) and methods of making and using the same
granted -
US 11407984
Methods for purification of arysulfatase A
granted -
US 11407990
Fusion proteins and methods for site-directed genome editing
granted -
US 11407997
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
granted -
US 11408001
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
granted -
US 11407825
NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof
granted -
US 11407998
Twist signaling inhibitor compositions and methods of using the same
granted -
US 11407705
Methods of making bempedoic acid and compositions of the same
granted -
US 11407822
Treatment of fibrodysplasia ossificans progressiva
granted -
US 11406618
Polymer-des-ethyl sunitinib conjugates
granted -
US 11406656
Methods and compositions for administration of iron
granted -
US 11406713
Xanthine oxidase inhibitor formulations
granted -
US 11406716
Modified RNAi agents
granted -
US 11407723
Selective histone deacetylase inhibitors for the treatment of human disease
granted -
US 11407789
Cell-penetrating compstatin analogs and uses thereof
granted -
US 11406646
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
granted -
US 11407753
Compounds for treating Huntington's disease
granted -
US 11406597
Fusogenic liposome-coated porous silicon nanoparticles
granted -
US 11406616
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
granted -
US 11406643
Targeting kinases for the treatment of cancer metastasis
granted -
US 11406697
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
granted -
US 11406663
Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
granted -
US 11406710
Constrained conditionally activated binding proteins
granted -
US 11406690
Adeno-associated virus factor VIII vectors
granted -
US 11406720
Fibroblast growth factor receptor 2-specific peptide reagents and methods
granted -
US 11406721
Compositions and methods for imaging cell populations
granted -
US 11406722
Nanodroplets with improved properties
granted -
US 11413350
Long-acting polymeric delivery systems
granted -
US 11414423
Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders
granted -
US 11413240
Methylene blue solution for the treatment of oral lesions
granted -
US 11414439
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 11414455
Toll-like receptor 2 ligands and methods of making and using thereof
granted -
US 11414488
Methods for treating cancer
granted -
US 11414644
Methods of recellularizing a tissue or organ for improved transplantability
granted -
US 11414489
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
granted -
US 11414494
Anti-GITR antibodies and uses thereof
granted -
US 11413255
Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles
granted -
US 11414496
Anti-CD38 binding domains
granted -
US 11413274
Methods and compositions associated with the granulocyte colony-stimulating factor receptor
granted -
US 11413303
Methods for treatment of arthritis
granted -
US 11414379
SPAK kinase inhibitors as neuroprotective agents
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.